Avoid common mistakes on your manuscript.
Correction to: Diabetes Ther (2018) 9:1491–1500 https://doi.org/10.1007/s13300-018-0456-7
In the original publication, Figure 3 was incorrectly published. The authors have updated figure 3 and the corrected Fig. 3 is given below.
Plots presenting indirect comparisons of empagliflozin versus other glucose-lowering drugs
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Balijepalli, C., Shirali, R., Kandaswamy, P. et al. Correction to: Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons. Diabetes Ther 10, 325–326 (2019). https://doi.org/10.1007/s13300-018-0543-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13300-018-0543-9